Ex Vivo Gamma Delta T Cell Populations

text
September 15, 2022

Inventors

Katharina Bergerhoff, Oxana Polyakova, Oliver Nussbaumer

Assignees

GammaDelta Therapeutics

Abstract

The invention relates to ex vivo methods of modulating Vδ1 T cells using anti-Vδ1 antibodies or fragments thereof.

CovalX Technology Used

Epitope Mapping
XL-MS

Contact our Scientific Team to Start the Conversation

Request A Call
Source
https://patents.google.com/patent/US20220290101A1
Back
Categories : Patents, Epitope Mapping
text
PREVIOUS : Novel Antibodies to a gamma variable 4 (Vγ4) chain of a γδ T cell receptor (TCR)
NEXT : Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis
text
CovalX
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.